pro-caspase3

17-Hydroxy sprengerinin C is a glycoside compound isolated from rhizomes of Polygonatum sibiricum with stronger anticancer activities. 17-Hydroxy sprengerinin C reduces the expression of Blc-2 and pro-caspase3 and increases the production of Bax.

Duocarmycin A, an antitumor antibiotic, is a DNA alkylator and efficiently alkylates adenine N3 at the 3′ end of AT-rich sequences in the DNA. Duocarmycin A, as a chemotherapeutic agent, results in HLC-2 cells typically apoptotic changes.

PAC-1 (Procaspase activating compound 1) has been used in trials studying the treatment of Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers, among others.

CASP3 Activator 1541 is an activator of the proenzyme forms of caspase-3, and induces cell death.

Procaspase-3 activator 1 is a potent activator of procaspase-3. It directly activates procaspase-3 through zinc chelation, inducing apoptosis and inhibiting cancer cell proliferation. Procaspase-3 activator 1 is applicable in research on non-small cell lung cancer (NSCLC) and melanoma.

Lb54 is an activator of caspase-3 and caspase-7 with an EC50 of 660.9 nM for human procaspase-3. It activates caspase-3/7, which cleaves Gasdermin D (GSDMD) at the aspartic acid residue 87 to produce a p10 fragment, thus preventing the formation of the pore-forming p30 fragment of GSDMD. By activating caspase-3/7, Lb54 inhibits GSDMD-mediated pyroptosis, thereby reducing inflammation and providing protection against sepsis. Additionally, Lb54 alleviates acute lung injury and suppresses systemic inflammation by inhibiting the maturation of monocyte-derived dendritic cells. Lb54 is applicable in sepsis-related research.

WF-210 is an effective activator of procaspase-3 that acts by inducing apoptosis in cancer cells and reducing tumor growth.

CB2 receptor agonist 8 (Compound 17) is an agonist of the cannabinoid receptor 2 (CB2 receptor). It shows cytotoxicity in U87, RPMI 8226, HL-60, and L929 cells with IC50 values of 91.03, 16.29, 23.51, and 564.6 μM, respectively. CB2 receptor agonist 8 activates caspase 3/7, increases the expression of pro-apoptotic genes BAX, BAD, BIM, and the tumor suppressor gene p53, and induces apoptosis in U87 cells. Additionally, it inhibits the migration of U87 cells.

TFGF-18 is a GSK-3β inhibitor with an IC50 of 0.59 μM. It suppresses microglial activation and the release of pro-inflammatory mediators induced by LPS by inhibiting GSK-3β and downstream p65/NF-κB signaling. TFGF-18 also prevents neuronal apoptosis and oxidative stress, reduces the expression of Bax, caspase-3, and cleaved-caspase-3, while increasing Bcl-2 expression. It offers neuroprotection by inhibiting neuroinflammation and alleviating cognitive impairment.